Piramal Pharma Ltd

Net loss of Piramal Pharma reported to Rs 8.83 crore in the quarter ended March 2026 as against net profit of Rs 153.50 crore during the previous quarter ended March 2025. Sales declined 0.08% to Rs 2751.77 crore in the quarter ended March 2026 as against Rs 2754.07 crore during the previous quarter ended March 2025. For the full year,net loss reported to Rs 325.94 crore in the year ended March 2026 as against net profit of Rs 91.13 crore during the previous year ended March 2025. Sales declined 3.08% to Rs 8869.08 crore in the year ended March 2026 as against Rs 9151.18 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales2751.772754.07 0 8869.089151.18 -3 OPM %16.7420.37 -10.3915.79 - PBDT437.15515.56 -15 851.321230.98 -31 PBT218.77272.80 -20 20.08414.64 -95 NP-8.83153.50 PL -325.9491.13 PL Powered by Capital Market - Live

Piramal Pharma Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 168.78, up 2% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.74% on the day, quoting at 24075.7. The Sensex is at 77243.68, up 0.76%. Piramal Pharma Ltd has added around 23.61% in last one month. Meanwhile, Nifty Pharma index of which Piramal Pharma Ltd is a constituent, has added around 4.1% in last one month and is currently quoting at 22580.1, up 2.49% on the day. The volume in the stock stood at 68.33 lakh shares today, compared to the daily average of 61.68 lakh shares in last one month. The benchmark April futures contract for the stock is quoting at Rs 169.6, up 2.1% on the day. Piramal Pharma Ltd is down 21.43% in last one year as compared to a 1.04% fall in NIFTY and a 5.64% fall in the Nifty Pharma index.The PE of the stock is 29.81 based on TTM earnings ending December 25.

Piramal Pharma Ltd is up for a third straight session in a row. The stock is quoting at Rs 163.99, up 6.62% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.75% on the day, quoting at 24195.15. The Sensex is at 77763.49, down 0.96%. Piramal Pharma Ltd has added around 20.51% in last one month. Meanwhile, Nifty Pharma index of which Piramal Pharma Ltd is a constituent, has added around 3.23% in last one month and is currently quoting at 22455.45, up 2.24% on the day. The volume in the stock stood at 422.04 lakh shares today, compared to the daily average of 30.77 lakh shares in last one month. The benchmark April futures contract for the stock is quoting at Rs 162.77, up 6.78% on the day. Piramal Pharma Ltd is down 25.42% in last one year as compared to a 0.21% fall in NIFTY and a 4.48% fall in the Nifty Pharma index.The PE of the stock is 27.73 based on TTM earnings ending December 25.

Piramal Pharma will hold a meeting of the Board of Directors of the Company on 28 April 2026.

Piramal Pharma Ltd rose for a third straight session today. The stock is quoting at Rs 149.59, up 2.13% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 1.57% on the day, quoting at 24216.6. The Sensex is at 78059.78, up 1.58%. Piramal Pharma Ltd has added around 7.84% in last one month. Meanwhile, Nifty Pharma index of which Piramal Pharma Ltd is a constituent, has added around 0.88% in last one month and is currently quoting at 22100.1, up 1.13% on the day. The volume in the stock stood at 16.87 lakh shares today, compared to the daily average of 32.69 lakh shares in last one month. The benchmark April futures contract for the stock is quoting at Rs 149.53, up 2.34% on the day. Piramal Pharma Ltd is down 32.57% in last one year as compared to a 3.33% gain in NIFTY and a 7.07% gain in the Nifty Pharma index.The PE of the stock is 26.4 based on TTM earnings ending December 25.

In a regulatory filing made in December last year, the company said that the United States Food and Drug Administration (US FDA) conducted a general good manufacturing practices (GMP) inspection of Piramal Pharma's Lexington (Kentucky, USA) facility from 03 December 2025 to 10 December 2025. At the conclusion of the inspection, the US FDA issued a Form-483, with four observations. These observations are related to enhancement in procedures and will be classified as a VAI (voluntary action indicated). The company is preparing a detailed response to the observations, which will be submitted to the US FDA within the stipulated timelines,' Piramal Pharma had said in a statement. Offering updates on the same, Piramal Pharma today (13 April 2026) said that the US FDA has issued an establishment inspection report (EIR) for the said manufacturing facility with VAI (voluntary action indicated). Receipt of said EIR marks successful closure of the inspection, the company stated. Piramal Pharma offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. The company a consolidated net loss of Rs 136.19 crore in the quarter ended December 2025 as against net profit of Rs 3.68 crore during the previous quarter ended December 2024. Sales declined 2.92% to Rs 2,139.87 crore in Q3 FY26 as compared with Q3 FY25. The scrip rose 0.68% to currently trade at Rs 147.10 on the BSE.

Piramal Pharma announced that US FDA has issued an Establishment Inspection Report (EIR) for its manufacturing facility located at Lexington, (Kentucky, USA) with VAI (Voluntary Action Indicated). Receipt of said EIR marks successful closure of the inspection.

Piramal Pharma Ltd is up for a third straight session in a row. The stock is quoting at Rs 142.92, up 1.31% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 1.5% on the day, quoting at 22956.8. The Sensex is at 74113.48, down 1.54%. Piramal Pharma Ltd has dropped around 6.47% in last one month. Meanwhile, Nifty Pharma index of which Piramal Pharma Ltd is a constituent, has dropped around 1.46% in last one month and is currently quoting at 22679.75, down 0.26% on the day. The volume in the stock stood at 49.25 lakh shares today, compared to the daily average of 31.49 lakh shares in last one month. The benchmark March futures contract for the stock is quoting at Rs 142.5, up 0.72% on the day. Piramal Pharma Ltd is down 36.41% in last one year as compared to a 2.39% drop in NIFTY and a 7.02% drop in the Nifty Pharma index.The PE of the stock is 25.42 based on TTM earnings ending December 25.Powered by Capital Market - Live

By combining the innovative waste anaesthesia gas capture, collection, and processing technology developed by Blue-Zone, with the global manufacturing and marketing capabilities of Piramal, this collaboration will support customers' efforts to minimize the environmental impact of volatile anaesthetics. This collaboration will also help ensure that these essential products remain the primary method of providing general anaesthesia for patients around the world. Pending regulatory approval in Europe of Blue-Zone's Phoenix Deltasorb waste anaesthetic gas capture system, Blue-Zone will offer these systems to PCC's customers in Europe, initially in France and Germany. Blue-Zone will be responsible for all activities involving the supply and use of its systems in healthcare facilities. PCC will process captured waste anaesthetic gas using Blue Zone's technology to produce Sevoflurane USP for human use in Canada. The parties anticipate that the scope of the waste anaesthetic gas capture, collection and recycling, and the marketing of Sevoflurane USP using waste anaesthetic gas, will expand into additional geographies. PCC is a global leader in anaesthesia, pain management and intrathecal therapy. PCC maintains a wide global footprint, delivering continuous supply to hospitals in more than 100 countries around the world. Piramal Pharma offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. The company a consolidated net loss of Rs 136.19 crore in the quarter ended December 2025 as against net profit of Rs 3.68 crore during the previous quarter ended December 2024. Sales declined 2.92% to Rs 2139.87 crore in Q3 FY26 as compared with Q3 FY25. The scrip shed 0.79% to currently trade at Rs 157.15 on the BSE. Powered by Capital Market - Live

Piramal Pharma announced the cessation of Subramanian Ramadorai (DIN: 00000002) as an independent director of the company with effect from 09 February 2026. Powered by Capital Market - Live